Why the study?
To evaluate ultrasound-determined non-alcoholic fatty pancreas disease severity as a risk factor for coronary heart disease and assess its predictive value for intermediate/high CHD risk compared with ultrasound-determined NAFLD severity.
Key points are not available for this paper at this time.
Comparison
US-determined NAFPD severity vs US-determined NAFLD severity
NAFPD severity may indicate higher CHD risk; leaves open its added predictive value over NAFLD.
Purpose To evaluate non-alcoholic fatty pancreas disease severity on ultrasound (US-determined NAFPD) as a risk factor for coronary heart disease (CHD) and to evaluate its predictive value for intermediate/high CHD risk compared with US-determined non-alcoholic fatty liver disease (US-determined NAFLD) severity.
No takes yet. Share an insight, caveat, or question.
An et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: